Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983521 | 0.92 | ALDH1A1 (0.48) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14379329 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14379331 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL2597530 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14983516 | 0.71 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL13998386 | 0.71 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL22095384 | 0.70 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14983520 | 0.69 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14983513 | 0.67 | CYP1A2 (0.42) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL14983519 | 0.67 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988403-B2 | Compositions and methods for treating cancer with aberrant lipogenic signaling | THOMAS JEFFERSON UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988403-B2 | Compositions and methods for treating cancer with aberrant lipogenic signaling | THOMAS JEFFERSON UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9750758-B2 | Compositions and methods for treating cancer with aberrant lipogenic signaling | THOMAS JEFFERSON UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750758-B2 | Compositions and methods for treating cancer with aberrant lipogenic signaling | THOMAS JEFFERSON UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170166593-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | THOMAS JEFFERSON UNIVERSITY (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166593-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | THOMAS JEFFERSON UNIVERSITY (US) | 2017-06-15 | — | — | US | disclosed |
| US-20160215002-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | THOMAS JEFFERSON UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160215002-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | THOMAS JEFFERSON UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160215002-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | SREBF1, SREBF2, OSBP | ALDH1A1 2147/4885HPGD 3030/4885HSD17B10 303/4885 |
| US-20170166593-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ABERRANT LIPOGENIC SIGNALING | SREBF1, SREBF2, OSBP | ALDH1A1 2014/4885HPGD 3100/4885HSD17B10 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.